{"id":"NCT00706849","sponsor":"Kastle Therapeutics, LLC","briefTitle":"Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of ISIS 301012 as Add-on Therapy in Heterozygous Familial Hypercholesterolemia Subjects With Coronary Artery Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2009-12","completion":"2010-05","firstPosted":"2008-06-30","resultsPosted":"2013-03-21","lastUpdate":"2016-09-09"},"enrollment":124,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Heterozygous Familial Hypercholesterolemia","Coronary Artery Disease"],"interventions":[{"type":"DRUG","name":"mipomersen sodium","otherNames":["ISIS 301012","Kynamroâ„¢"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Mipomersen","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether mipomersen safely and effectively lowers low-density lipoprotein cholesterol (LDL-C) in patients with Heterozygous Familial Hypercholesterolemia (HeFH) and coronary artery disease (CAD) who are already on a stable dose of other lipid-lowering agents (including maximally tolerated statin therapy).","primaryOutcome":{"measure":"Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point","timeFrame":"Baseline (the average of the screening and Day 1 pre-treatment assessments) and the Primary Efficacy Time point (PET; Week 28 or the post-baseline visit closest to 14 days after the last dose).","effectByArm":[{"arm":"Placebo","deltaMin":5.17,"sd":18.02},{"arm":"Mipomersen","deltaMin":-28.02,"sd":26.99}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":2},"locations":{"siteCount":48,"countries":["United States","Canada"]},"refs":{"pmids":["23060426","27578134","25614280"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":41},"commonTop":["Injection site pain","Injection site erythema","Injection site haematoma","Fatigue","Injection site pruritus"]}}